KR101093863B1 - A cosmetic composition comprising an extract of the tissue cultured morinda citirifolia callus extracts and a preparation method of the extract - Google Patents

A cosmetic composition comprising an extract of the tissue cultured morinda citirifolia callus extracts and a preparation method of the extract Download PDF

Info

Publication number
KR101093863B1
KR101093863B1 KR1020090020815A KR20090020815A KR101093863B1 KR 101093863 B1 KR101093863 B1 KR 101093863B1 KR 1020090020815 A KR1020090020815 A KR 1020090020815A KR 20090020815 A KR20090020815 A KR 20090020815A KR 101093863 B1 KR101093863 B1 KR 101093863B1
Authority
KR
South Korea
Prior art keywords
cultured
morinda
tissue cultured
extract
citirifolia
Prior art date
Application number
KR1020090020815A
Other languages
Korean (ko)
Other versions
KR20100102437A (en
Inventor
최종완
정민석
양다운
Original Assignee
주식회사 한국화장품제조
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 한국화장품제조 filed Critical 주식회사 한국화장품제조
Priority to KR1020090020815A priority Critical patent/KR101093863B1/en
Publication of KR20100102437A publication Critical patent/KR20100102437A/en
Application granted granted Critical
Publication of KR101093863B1 publication Critical patent/KR101093863B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus) 추출물을 포함하는 화장료 조성물 및 그 제조방법에 관한 것으로서, 피부노화방지, 피부빛 개선 및 피부손상에 대한 피부보호를 위한 화장료 조성물에 유용하게 사용될 수 있다.The present invention relates to a cosmetic composition comprising a tissue cultured noni cultured cell (Tissue cultured Morinda citirifolia callus) extract, and a method of manufacturing the same, which is useful for a cosmetic composition for preventing skin aging, improving skin light, and protecting skin against skin damage. Can be used.

화장료, 노니, 조직배양, 항산화, 세포보호, 미백, 주름 Cosmetics, Noni, Tissue Culture, Antioxidant, Cell Protection, Whitening, Wrinkles

Description

조직 배양한 노니 배양세포 추출물을 포함하는 화장료 조성물 및 상기 조직 배양한 노니 배양세포 추출물의 제조방법{A COSMETIC COMPOSITION COMPRISING AN EXTRACT OF THE TISSUE CULTURED MORINDA CITIRIFOLIA CALLUS EXTRACTS AND A PREPARATION METHOD OF THE EXTRACT} A cosmetic composition comprising a tissue cultured noni cultured cell extract and a method for producing the tissue cultured noni cultured cell extract {A COSMETIC COMPOSITION COMPRISING AN EXTRACT OF THE TISSUE CULTURED MORINDA CITIRIFOLIA CALLUS Extra

본 발명은 세포보호, 항산화, 주름개선 및 미백 효과가 우수한 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus) 추출물을 포함하는 화장료 조성물 및 상기 조직 배양한 노니 배양세포 추출물의 제조방법에 관한 것이다.The present invention relates to a cosmetic composition comprising a tissue cultured Morinda citirifolia callus extract excellent in cell protection, anti-oxidation, anti-wrinkle and whitening effects, and a method for preparing the tissue cultured noni culture cell extract.

피부는 외부자극으로부터 몸을 보호해 주는 기능을 가진다. 이러한 외부 자극, 즉 환경적, 물리적, 화학적 자극은 피부기능을 저하시키고 피부노화의 원인이 된다. 피부노화의 원인은 크게 내인성 노화와 외인성 노화, 두가지로 나뉜다. 내인성 노화는 나이가 들면서 생체시계에 맞춰 피부세포에 관여하는 유전인자의 작용으로 피부재생 속도 및 콜라겐 합성이 점점 느려지면서 노화가 진행되는 것이다. 외인성 노화는 자외선에 피부노출, 공해, 활성산소 및 기타 스트레스 등 외부적 요인에 의해 노화가 발생하는 경우이다. 외인성 노화는 내인성 노화와 달리 피부가 두껍게 되고 색소침착이 많이 일어난다. Skin protects the body from external stimuli. These external stimuli, that is, environmental, physical and chemical stimuli, deteriorate skin function and cause skin aging. There are two main causes of skin aging: endogenous aging and exogenous aging. Endogenous aging is an action of genetic factors involved in skin cells in accordance with the biological clock as the body ages, and aging progresses as skin regeneration rate and collagen synthesis become slower and slower. Exogenous aging is when aging is caused by external factors such as skin exposure, pollution, free radicals and other stresses. Exogenous aging, unlike endogenous aging, thickens the skin and causes a lot of pigmentation.

이러한 노화가 진행되면 피부의 진피조직이 약해지고 피부 세포 결합도가 현저하게 떨어진다. 또 피부 탄력에 관여하는 콜라겐과 엘라스틴의 양이 급격하게 줄어들고 점차 얼굴의 형태가 변하고 피부 건성도도 매우 심해져서 피부가 거칠어지고 주름도 깊어진다. 또한 신진대사가 저하되면서 혈액이 피부에 제대로 공급되지 않아 피부가 칙칙해 보인다. 이러한 피부 현상을 방지하면서 건강하고 아름다운 피부를 유지하기 위한 노력이 계속되고 있다. 최근 피부 개선을 위한 연구 노력은 부작용이 없고 인체 친화적이며 체질과 상관없이 안심하고 사용할 수 있는 식물추출물을 이용한 소재 개발이 활발하게 연구되어 오고 있다.As the aging progresses, the dermal tissue of the skin is weakened and the degree of skin cell binding is significantly reduced. In addition, the amount of collagen and elastin involved in the elasticity of the skin is drastically reduced, the shape of the face gradually changes, and the dryness of the skin becomes very severe, resulting in rough skin and deep wrinkles. In addition, as metabolism decreases, blood is not supplied properly to the skin, making the skin look dull. Efforts have been made to maintain healthy and beautiful skin while preventing such skin phenomenon. Recently, research efforts to improve skin have been actively studied for developing materials using plant extracts that have no side effects, are friendly to human beings, and can be used safely regardless of constitution.

일반적으로 천연 식물추출물을 함유하는 기능성 화장품은 식물들이 생육할 수 있는 조건인 열대우림기후로부터 냉대, 한대 기후에서 생육하는 모든 식물을 사용할 수 있다. 식물들은 각각의 기후에 적응하여 그 조건에서 최적의 생체 메커니즘을 통해서 생육하게 된다. 따라서 같은 종의 식물이라도 생육하는 위도에 따른 일조량, 기온, 강수량 등과 토양의 산도, 비옥도 등 기후조건과 계절별, 식물체의 부위별로 식물내부의 2차대사산물과 같은 유효성분들의 종류와 함량이 다를 수 있다. 뿐만 아니라, 제조에 따른 공급을 충족시키기가 어렵고, 가공비용이 많이 드는 등의 단점을 극복하기 어렵다. 이러한 여러 가지 어려움을 개선하기 위해 최근 식물배양 기술이 이용한 화장품 원료개발이 두드러지고 있다. In general, functional cosmetics containing natural plant extracts can use any plant that grows in cold, cold climates from the rainforest climate, which is the condition under which plants can grow. Plants adapt to each climate and grow under the optimal biomechanisms under those conditions. Therefore, even the same species of plants may have different types and contents of active ingredients such as secondary metabolites in plants by climatic conditions such as sunshine, temperature, precipitation, soil acidity, fertility, soil, fertility, etc. have. In addition, it is difficult to meet the disadvantages, such as difficult to meet the supply according to the manufacturing, high processing costs. In order to improve these various difficulties, the development of cosmetic raw materials used by plant culture technology is emerging.

한편, 꼭두서니과의 상록관목인 노니(Noni: Morinda Citrifolia)는 2000년 동안 폴리네시아, 남태평양 군도, 타이티, 하와이, 말레이시아, 중국 등지에서 전 통 약제로 널리 사용되어 왔으며, 질병에 대한 광범위한 효과가 있는 것으로 알려져 있다. 또한 우리나라에서는 동의보감에 해파극(海巴戟), 파극천(巴戟天)으로 기록되어 있으며 예부터 사용되어 왔다. 노니는 화산 토양에 뿌리를 깊이 내리고 자라는 나무로, 작은 덤불 모양에서부터 9m 정도 높이의 나무까지 다양한 모습을 하고 있다. 일년 내내 아름답고 향기로운 하얀 꽃을 피우며 열매가 익으면 독특한 냄새와 맛이 나고 열매는 섬유질을 상당량 포함하고 있는데 약 10cm 정도로 감자를 닮았다. 노니는 오랜 세월 동안 폴리네시아인들이 민간요법으로 사용해 온 전통약제로 열매, 잎사귀, 뿌리, 줄기, 씨 등 나무의 모든 부분이 사용되어 왔으며, 남태평양 지역의 고대문헌에 의하면 최고의 자연치료제로 기록되어 있다. 이러한 노니의 효능은 많은 연구를 통해 밝혀져 있다. 노니는 면역체계를 강화시켜주며 인체 내 유해산소를 자체 제거하도록 도와주는 우수한 산화방지제이며 피를 정화시키고 손상된 부위를 치료하며, 세포 기능을 강화해준다. 게다가 혈압을 안정시키며 콜레스테롤 수치를 낮추고 심신을 안정시키는 등 1백 가지 이상의 의학적 효능들이 있는 것으로 이미 입증된 바 있다. 그러나 조직 배양한 노니 캘러스의 효능에 대해서 보고된 과학적 실험 결과는 미비하다. 또한 화장료 성분으로 응용하기 위한 연구결과도 보고된 바 없다. 본 실험에서 사용된 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)란 노니의 잎으로부터 식물조직배양기술을 이용하여 캘러스를 유도하고 영양액에 배양한 것을 의미한다. On the other hand, Noni ( Morinda Citrifolia ), an evergreen shrub of the horned pod , has been widely used as a traditional medicine in Polynesia, the South Pacific Islands, Taiti, Hawaii, Malaysia, and China for 2000 years, and is known to have a wide range of effects on diseases. have. Also, in Korea, it is recorded as Hae-gaeok and Paeokcheon in the agreement and has been used since ancient times. Noni is a tree that grows deeply rooted in volcanic soil, ranging from small bushes to trees about 9 meters high. It blooms beautiful and fragrant white flowers all year round. When the fruit ripens, it has a unique smell and taste, and the fruit contains a significant amount of fiber, which resembles potatoes about 10cm long. Noni is a traditional medicine that has been used by Polynesians for many years as a folk remedy, and all parts of the tree, including fruit, leaves, roots, stems, and seeds, have been used. The efficacy of these noni has been found in many studies. Noni is an excellent antioxidant that strengthens the immune system and helps remove harmful oxygen from the body. It purifies blood, heals damaged areas, and enhances cellular function. In addition, it has been proven to have more than 100 medical benefits, including stabilizing blood pressure, lowering cholesterol and stabilizing the mind and body. However, the reported scientific experiments on the efficacy of tissue cultured Noni callus are insufficient. In addition, there have been no reports on the application of cosmetic ingredients. Tissue cultured Morinda citirifolia callus (tissue cultured Morinda citirifolia callus) used in this experiment means that the callus is derived from the leaves of Noni by using plant tissue culture technology and cultured in nutrient solution.

이에, 본 발명자들은 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물의 효능효과 평가를 중심으로 하여, 식물배양 기술을 이 용한 화장품으로서의 응용 가능성에 대한 연구를 계속하여 본 발명을 완성하였다.Accordingly, the present inventors have completed the present invention by continuing to study the applicability as a cosmetic using plant culture technology, mainly on the evaluation of the efficacy effect of tissue cultured Morinda citirifolia callus extract.

본 발명은 세포보호, 항산화, 주름개선 및 미백 효과를 가지는 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물을 포함하는 화장료 조성물 및 그 제조방법을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a cosmetic composition comprising a tissue cultured Morinda citirifolia callus extract having a cytoprotective , antioxidant, anti-wrinkle and whitening effect and a method for producing the same.

본 발명은, 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물을 포함하는 화장료 조성물을 제공한다.The present invention provides a cosmetic composition comprising a tissue cultured noni cultured cells (tissue cultured Morinda citirifolia callus) extract.

또한, 본 발명은 a)조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)를 정제수, C1 내지 C4의 알코올 및 C1 내지 C5 알킬렌글리콜로 이루어진 군으로부터 선택되는 1종 이상의 추출용매에 3 내지 30일 동안 침적하여 침적용액을 형성하는 단계; 및 b)상기 침적용액을 여과하여 조직 배양한 노니 배양세포 추출물을 얻는 단계를 포함하는 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물의 제조방법을 제공한다.In addition, the present invention a) tissue cultured noni cultured cells (Tissue cultured Morinda citirifolia callus) 3 to 30 in at least one extraction solvent selected from the group consisting of purified water, C1 to C4 alcohol and C1 to C5 alkylene glycol. Depositing for days to form an immersion solution; And b) provides a method for producing a tissue cultured noni cultured cell (tissue cultured Morinda citirifolia callus) extract comprising the step of obtaining the noni cultured cell cultured by filtration of the deposition solution.

본 발명의 화장료 조성물은 천연 추출물을 이용하기 때문에 피부 자극으로부터 자유롭고, 세포보호효과와 항산화, 주름개선 및 미백 효과를 가지므로 피부노화방지, 피부개선 및 보호에 매우 효과적이다. Since the cosmetic composition of the present invention uses a natural extract, it is free from skin irritation, and has a cytoprotective effect, antioxidant, anti-wrinkle and whitening effect, and thus is very effective in preventing skin aging, skin improvement and protection.

이하, 본 발명은 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus) 추출물을 포함하는 화장료 조성물을 설명한다.Hereinafter, the present invention describes a cosmetic composition comprising an extract of tissue cultured Morinda citirifolia callus.

본 발명의 화장료 조성물은 천연의 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus) 추출물을 함유함으로써, 각종 외부 자극으로부터 피부를 보호하여 피부를 부드럽고 윤기 있게 가꾸어 주며, 피부기능 개선에 도움을 준다.The cosmetic composition of the present invention contains natural tissue cultured noni cultured cell culture (Tissue cultured Morinda citirifolia callus) extract, protects the skin from various external stimuli, makes the skin soft and shiny, and helps improve skin function.

여기서, 본 발명에 사용된 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)는 충북대학교 첨단원예기술개발연구센터에서 제공받은 것으로 건조시켜 사용하였다. Here, tissue cultured Morinda citirifolia callus (tissue cultured Morinda citirifolia callus) used in the present invention was used that was provided by Chungbuk National University Advanced Horticultural Technology Development Research Center.

본 발명의 화장료 조성물은, 조성물 총 중량에 대하여 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus) 추출물을 0.1 내지 10.0 중량%로 포함하는 것이 바람직하다. 상술한 범위를 만족하면, 유의성 있는 효과, 즉 각종 외부 자극으로부터 피부를 보호하여 피부를 부드럽고 윤기 있게 가꾸어 주며, 피부기능 개선에 도움을 주는 효과가 나타난다. 또한, 최종 제품에서의 추출물의 고유 냄새, 색상 등을 고려할 때 상기와 같은 범위로 포함되는 것이 유리하다.The cosmetic composition of the present invention preferably comprises 0.1 to 10.0 wt% of tissue cultured Morinda citirifolia callus extract based on the total weight of the composition. If the above-mentioned range is satisfied, a significant effect, that is, protects the skin from various external stimuli, makes the skin soft and shiny, and helps to improve skin function. In addition, when considering the intrinsic smell, color, etc. of the extract in the final product is advantageously included in the above range.

상기 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물은 조직 배양한 노니 배양세포를 정제수, C1 내지 C4의 알코올 및 C1 내지 C5의 알킬렌글리콜로 이루어진 군으로부터 선택되는 1종 이상의 용매를 사용하여 추출하는 것이 바람직하다.The tissue cultured noni cultured cells (Tissue cultured Morinda citirifolia callus) extract is a tissue cultured noni cultured cells using at least one solvent selected from the group consisting of purified water, C1 to C4 alcohol and C1 to C5 alkylene glycol. It is preferable to extract by.

본 발명의 화장료 조성물을 첨가할 수 있는 제품으로는, 예를 들어, 각종 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 영양로션, 마사 지크림, 영양크림, 핸드크림, 파운데이션, 메이크업베이스, 트윈케익, 마스카라, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저 등이 있으며, 이로 한정되는 것은 아니다. 본 발명의 화장품 조성물이 상술한 형태의 제형으로 제조될 때, 그 제형의 제제화에 필요하고 적절한 각종의 기제와 첨가물을 함유할 수 있다. 또한, 이들 성분의 종류와 양은 당 업자에 의해 용이하게 선정될 수 있다. As a product to which the cosmetic composition of the present invention can be added, for example, various skin lotions, skin softeners, skin toners, astringents, lotions, milk lotions, nutrition lotions, massage creams, nutrition creams, hand creams, foundations, Makeup base, twin cake, mascara, essence, nutrition essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser, but is not limited thereto. When the cosmetic composition of the present invention is prepared in a formulation of the form described above, it may contain various bases and additives necessary and appropriate for the formulation of the formulation. In addition, the type and amount of these components can be easily selected by those skilled in the art.

이하, 본 발명의 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus) 추출물의 제조방법을 설명한다.Hereinafter, a method of preparing a tissue cultured Noni cultured cell (Tissue cultured Morinda citirifolia callus) extract of the present invention.

또한, 본 발명은 a)조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)를 정제수, C1 내지 C4의 알코올 및 C1 내지 C5의 알킬렌글리콜로 이루어진 군으로부터 선택되는 1종 이상의 추출용매에 3~30일 동안 침적하여 침적용액을 형성하는 단계; 및 b)상기 침적용액을 여과하여 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물을 얻는 단계를 포함한다. In addition, the present invention a) tissue cultured noni cultured cells (Tissue cultured Morinda citirifolia callus) 3 ~ in one or more extraction solvents selected from the group consisting of purified water, C1 to C4 alcohol and C1 to C5 alkylene glycol. Depositing for 30 days to form an immersion solution; And b) filtering the immersion solution to obtain a tissue cultured Morinda citirifolia callus extract.

상기 a)단계에서는, 상기 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)가 건조된 상태인 것이 바람직하다. 상기 침적시간은 10 내지 20일인 것이 바람직하다.In step a), the tissue cultured noni cultured cells (tissue cultured Morinda citirifolia callus) is preferably in a dried state. The deposition time is preferably 10 to 20 days.

상기 추출용매는, 상기 건조된 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)의 중량에 대비하여, 10 내지 20배(w/w)로 사용하는 것이 바람직하다.The extractant is preferably used in an amount of 10 to 20 times (w / w) based on the weight of the dried tissue cultured Noni culture cells (tissue cultured Morinda citirifolia callus).

상기 C1 내지 C4의 알코올은 에탄올인 것이 바람직하고, 상기 C1 내지 C4의 알킬렌글리콜은 1,3-부틸렌글리콜, 프로필렌글리콜 및 펜틸렌글리콜로 이루어진 군에서 선택되는 1종 이상인 것이 바람직하다. The alcohol of C1 to C4 is preferably ethanol, and the alkylene glycol of C1 to C4 is preferably one or more selected from the group consisting of 1,3-butylene glycol, propylene glycol and pentylene glycol.

또한, 상기 추출용매가 상기 알코올과 알킬렌글리콜의 혼합용매일 경우, 이들의 혼합비(w/w)가 6:4 내지 9:1인 것이 바람직하다. 상기 알코올과 알킬렌글리콜의 혼합용매의 경우, 함유량이 상술한 범위일 경우, 원하는 유용성분만을 추출하는데 보다 효율적인 극성을 갖는다. 여기서, 상기 알코올과 알킬렌글리콜의 혼합용매에 사용되는 알코올의 농도는 60 내지 100%인 것이 바람직하다.In addition, when the extraction solvent is a mixed solvent of the alcohol and alkylene glycol, it is preferable that their mixing ratio (w / w) is 6: 4 to 9: 1. In the case of the mixed solvent of the alcohol and the alkylene glycol, when the content is in the above-described range, it has a more efficient polarity to extract only the desired useful components. Here, the concentration of the alcohol used in the mixed solvent of the alcohol and alkylene glycol is preferably from 60 to 100%.

또한, 상기 추출용매는 상기 정제수와 상기 알킬렌글리콜의 혼합용매일 수 있는데, 이들의 혼합비가 3:7 내지 1:9인 것이 바람직하다. In addition, the extraction solvent may be a mixed solvent of the purified water and the alkylene glycol, the mixing ratio thereof is preferably 3: 7 to 1: 9.

상기 추출용매가 단독용매일 경우, 바람직하게는 에탄올이고, 혼합용매일 경우, 알코올과 알킬렌글리콜의 혼합용매, 바람직하게는 에탄올과 1,3-부틸렌글리콜, 에탄올과 프로필렌글리콜 또는 에탄올과 펜틸렌글리콜의 혼합용매이고, 더 바람직하게는 에탄올과 1,3-부틸렌글리콜 또는 에탄올과 펜틸렌글리콜의 혼합용매이다.When the extraction solvent is a single solvent, preferably ethanol, in the case of a mixed solvent, a mixed solvent of alcohol and alkylene glycol, preferably ethanol and 1,3-butylene glycol, ethanol and propylene glycol or ethanol and pen It is a mixed solvent of styrene glycol, More preferably, it is a mixed solvent of ethanol and 1, 3- butylene glycol or ethanol and pentylene glycol.

상기 b)단계는 상기 추출용매를 제거하는 단계를 더 포함하는 것이 바람직하다. The step b) preferably further comprises the step of removing the extraction solvent.

본 발명의 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus) 추출물은, 상기 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물을 사람섬유아세포에 처리하여 피부자극에 대한 세포독성효과를 조사하는 단계, 상기 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물을 사람섬유아세포에 처리하여 외부자극에 대한 세포보호효과를 조사하는 단계, 상기 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물을 사람섬유아세포에 처리하여 콜라겐 생합성에 따른 피부노화방지효과를 조사하는 단계, 타이로시나제 억제에 따른 피부미백개선효과를 조사하는 단계로 이루어진 군에서 선택되는 1종 이상의 단계로 활용될 수 있다.The tissue cultured Noni cultured Morinda citirifolia callus extract of the present invention is treated with the tissue cultured Noni cultured Morinda citirifolia callus extract on human fibroblasts to investigate the cytotoxic effect on skin irritation. In the step, the tissue cultured noni cultured cells (Tissue cultured Morinda citirifolia callus) extract to the human fibroblasts to investigate the cytoprotective effect on external stimulation, the tissue cultured noni cultured cells (tissue cultured Morinda citirifolia callus) The extracts are treated with human fibroblasts to investigate the anti-aging effect of collagen biosynthesis and the skin whitening improvement effect of tyrosinase inhibition. Can be.

이하, 본 발명을 제조예, 시험예, 및 실시예 등을 통하여 더욱 상세하게 설명한다. 그러나 하기에 기재된 제조예, 시험예, 및 실시예 등은 본 발명을 예시하기 위한 것으로서 본 발명은 이들에 의해 한정되지 않고 다양하게 수정 및 변경될 수 있다.Hereinafter, the present invention will be described in more detail with reference to Preparation Examples, Test Examples, Examples, and the like. However, the production examples, test examples, examples, and the like described below are for illustrating the present invention, and the present invention is not limited thereto and may be variously modified and changed.

제조예1 내지 제조예4, 비교제조예1 내지 비교제조예4: 조직 배양한 노니 배양세포(tissue cultured Preparation Example 1 to Preparation Example 4, Comparative Preparation Example 1 to Comparative Preparation Example 4: Tissue cultured noni cultured cells (tissue cultured Morinda citirifoliaMorinda citirifolia callus)추출물의 제조 callus) Preparation of extract

조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)와 노니(Morinda citrifolia)를 각각 물로 씻어 거즈로 물기를 제거한 후, 건조 및 세절하여 준비하였다. 상기 준비된 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)와 노니(Morinda citrifolia)를 표 1에 기재된 함량으 로, 표 1에 기재된 함량으로 존재하는 혼합용매에 2주간 침적하여 숙성하였다. 그 후 여과지(일본 ToyoroshiKaisha, Ltd.에서 시판되는 5C, 185㎜)에 여과하고 에탄올을 증발시켜 여액 상태인 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus) 추출물와 노니(Morinda citrifolia) 추출물을 수득하였다.Tissue cultured noni cultured cells (Tissue cultured Morinda citirifolia callus) and Noni (Morinda citrifolia ) were each washed with water to remove the water with gauze, and then dried and prepared. The tissue cultured Noni culture cells (tissue cultured Morinda citirifolia callus) and Noni (Morinda citrifolia ) were prepared by immersing for 2 weeks in a mixed solvent present in the content shown in Table 1 to the content shown in Table 1. Thereafter, the resultant was filtered on filter paper (5C, 185 mm commercially available from Toyoroshi Kaisha, Ltd., Japan), and ethanol was evaporated to obtain tissue cultured Morinda citirifolia callus extract and Noni (Morinda citrifolia ) extract in the filtrate state. .

건조된 조직 배양한 노니 배양세포 (g)Noni cultured cells in dried tissue culture (g) 건조된 노니(g)Dried Noni (g) 추출용매(g)Extraction solvent (g) 종류(혼합비)Type (mixing ratio) 함량content 제조예1Preparation Example 1 2020 -- b-1:b-2=7:3b-1: b-2 = 7: 3 980980 제조예2Preparation Example 2 2020 -- b-1:b-2=6:4b-1: b-2 = 6: 4 980980 제조예3Preparation Example 3 2020 -- b-1:b-3=7:3b-1: b-3 = 7: 3 980980 제조예4Production Example 4 2020 -- b-1:b-3=6:4b-1: b-3 = 6: 4 980980 비교제조예1Comparative Production Example 1 -- 2020 b-1:b-2=7:3b-1: b-2 = 7: 3 980980 비교제조예2Comparative Production Example 2 -- 2020 b-1:b-2=6:4b-1: b-2 = 6: 4 980980 비교제조예3Comparative Production Example 3 -- 2020 b-1:b-3=7:3b-1: b-3 = 7: 3 980980 비교제조예4Comparative Production Example 4 -- 2020 b-1:b-3=6:4b-1: b-3 = 6: 4 980980

b-1: 70% 에탄올 b-2: 1,3-부틸렌글리콜b-1: 70% ethanol b-2: 1,3-butylene glycol

b-3: 프로필렌글리콜b-3: propylene glycol

시험예1: 조직 배양한 노니 배양세포(tissue cultured Test Example 1: tissue cultured noni tissue cells Morinda citirifoliaMorinda citirifolia callus)추출물의 세포독성 측정 callus) measurement of cytotoxicity of extracts

제조예1와 비교제조예1에 대한 세포독성 시험을 통해, 안전성을 평가하였다.Safety was evaluated through the cytotoxicity test for Preparation Example 1 and Comparative Preparation Example 1.

<세포 배양 (Cell culture)>Cell culture

ATCC사로부터 구입한 CCD-1064sk 사람섬유아세포를 10% 우태아혈청(FBS), 1% 페니실린-스트렙토마이신(penicillin-streptomycin)을 첨가한 이스코브스 모디파이드 둘베코스 미듐(Iscove's modified Dulbeco's medium: IMDM)으로 10㎝ 세포 배양접시에 10㎖의 배지로 37℃, 5% CO2 배양기에서 세포가 70 내지 80% 합류(confluency)가 되도록 배양하였다. 배지는 일주일에 두 번씩 갈아주고, 합류에 도달한 세포는 트립신-EDTA(trypsin-EDTA)를 사용하여 트립신처리(trypsinization)를 한 후 계대 배양하여 유지하였다. 상기에서 배양된 사람섬유아세포를 96-멀티웰 플레이트(96-multiwell plate)에 각각 1×104 세포/웰로 분주하고 24시간 배양하였다. 배양된 세포의 배지를 2% FBS 배지로 교체하고 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물인 제조예1과 노니(Morinda citrifolia) 추출물인 비교제조예1을 각각 처리 농도별로 배지에 희석하여 처리한 후 48시간 동안 CO2 인큐베이터에서 배양하였다.CCD-1064sk human fibroblasts purchased from ATCC were used with Iscove's modified Dulbeco's medium with 10% fetal calf serum (FBS) and 1% penicillin-streptomycin. ) Were cultured in a 10 cm cell culture dish with 10 ml of medium at 37 ° C. in a 5% CO 2 incubator so that the cells were 70-80% confluent. The medium was changed twice a week, and the cells reached the confluence were maintained by passage culture after trypsinization using trypsin-EDTA. Human fibroblasts cultured above were divided into 96 × multiwell plates at 1 × 10 4 cells / well and incubated for 24 hours. In the culture medium by replacing the medium of the cultured cells in 2% FBS medium and the tissue culture by say cell culture (tissue cultured Morinda citirifolia callus) extract of Preparation Example 1 and noni (Morinda citrifolia) extract of Comparative Production Example 1 Each concentration After dilution treatment, the cells were incubated in a CO 2 incubator for 48 hours.

시험예 1-1: 세포독성효과의 측정(MTT assay)Test Example 1-1: Measurement of Cytotoxic Effect (MTT assay)

배양이 끝난 세포에, PBS(phosphate buffered saline)에 용해한 MTT 저장(stock) 용액(5 mg/㎖)을 새로운 배지에서 10배 희석하고, 이 용액을 세포 각각의 웰에 100㎕씩 첨가하여 37℃에서 4시간 반응시켰다. 반응 후 살아있는 세포는 미토콘드리아에 존재하는 탈수소 효소에 의해 노란색의 수용성 기질인 MTT [3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide]가 비수용성의 MTT-포마즌 (MTT-formazan) 결정으로 환원되므로 이것의 양을 재면 세포 생존율을 측정할 수 있다. 배양 상등액을 제거하고 각각의 웰에 DMSO 200㎕를 첨가하여 세포에서 생성된 MTT-포마즌 결정체를 용해시킨 후 흡수분광광도계(UVmax, Molecular Device, USA)로 포마즌의 흡광도가 최대가 되는 시험필터(Test filter)인 540㎚의 파장에서의 O.D값과 참조필터(Reference filter)인 630㎚ 파장의 O.D값을 측정하여 그 차이값의 흡광도를 구하였다 (참고문헌 The EMBO Journal(2002)21, 2407-2417외 다수). 세포 독성은 흡광도의 백분율로 나타내었다.To the cultured cells, MTT stock solution (5 mg / ml) dissolved in PBS (phosphate buffered saline) was diluted 10-fold in fresh medium, and 100 µl of each solution was added to each well of the cell at 37 ° C. The reaction was carried out for 4 hours. After the reaction, the living cells were dehydrated by the dehydrogenase present in the mitochondria and the yellow water-soluble substrate MTT [3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium-bromide] was insoluble in water. Since it is reduced to (MTT-formazan) crystals, the amount of this can be measured to measure cell viability. Remove the culture supernatant and add 200 μl of DMSO to each well to dissolve the MTT-formenic crystals produced in the cells, and then use the absorption spectrophotometer (UVmax, Molecular Device, USA) to filter the maximum absorbance of the formazin. The absorbance of the difference value was obtained by measuring the OD value at a wavelength of 540 nm as a test filter and a 630 nm wavelength as a reference filter (The EMBO Journal (2002) 21, 2407). -2417 and many more). Cytotoxicity is expressed as a percentage of absorbance.

※ 세포생존율(%) = (시료 처리군 흡광도/무처리군 흡광도)×100※ Cell survival rate (%) = (Sample absorbance / untreated group absorbance) × 100

로(Raw) 데이터를 토대로 무처리군의 흡광도와 시료 처리군의 흡광도의 평균을 계산하여 표준편차를 구하였다.The standard deviation was obtained by calculating the average of the absorbance of the untreated group and the absorbance of the sample treated group based on raw data.

MTT assayMTT assay O.D. Mean ± S.D.
(% of 대조군)
OD Mean ± SD
(% of control)
검액농도 (W/W%)Sample concentration (W / W%) 대조군Control group 1One 0.50.5 0.10.1 0.050.05 0.010.01 제조예1:
조직 배양한 노니 배양세포
Preparation Example 1:
Tissue Cultured Noni Culture Cells
0.404±0.09
(100.0)
0.404 ± 0.09
(100.0)
0.383±0.013
(94.80)
0.383 ± 0.013
(94.80)
0.405±0.011
(100.25)
0.405 ± 0.011
(100.25)
0.428±0.008
(105.94)
0.428 ± 0.008
(105.94)
0.436±0.014
(107.92)
0.436 ± 0.014
(107.92)
0.445±0.010
(110.15)
0.445 ± 0.010
(110.15)
비교제조예1:
노니
Comparative Production Example 1:
Noni
0.404±0.09
(100.0)
0.404 ± 0.09
(100.0)
0.371±0.017
(91.83)
0.371 ± 0.017
(91.83)
0.408±0.012
(100.99)
0.408 ± 0.012
(100.99)
0.424±0.013
(104.95)
0.424 ± 0.013
(104.95)
0.430±0.009
(106.44)
0.430 ± 0.009
(106.44)
0.441±0.011
(109.16)
0.441 ± 0.011
(109.16)

시험예 1-2: 세포독성효과의 측정(Neutral Red assay)Test Example 1-2: Measurement of Cytotoxic Effects (Neutral Red assay)

배양이 끝난 세포에 각각의 웰에 뉴트랄 레드(Neutral Red, Sigma-Aldrich, USA) 50㎍/㎖를 첨가하고 3시간 동안 반응시켰다. 뉴트랄 레드는 완전히 살아있는 세포 또는 손상 받지 않는 세포의 리소좀에 농축된다. 반응 후, 세포를 1.0% 포르말린/1.0% 염화칼륨으로 고정한 다음 1.0% 아세트산/50% 에탄올 용액을 첨가하여 뉴트랄 레드를 추출하였다. 추출된 뉴트랄 레드를 흡수분광광도계(UVmax, Molecular Device, USA)를 이용하여 540-630㎚의 농도 별 세포독성 값을 측정하여 하기 표 2에 나타내었다 세포 독성은 흡광도의 백분율로 나타냈으며 3로트(lot)로 3회 실시하였다. Neutral Red (Neutral Red, Sigma-Aldrich, USA) was added to the cells after the culture was incubated for 3 hours. Neutral Red is concentrated in the lysosomes of completely living or intact cells. After the reaction, cells were fixed with 1.0% formalin / 1.0% potassium chloride and then neutral red was extracted by adding 1.0% acetic acid / 50% ethanol solution. The extracted neutral red was measured by absorbance spectrophotometer (UVmax, Molecular Device, USA) to measure the cytotoxicity value of each concentration of 540-630 nm. Table 2 shows the cytotoxicity expressed as a percentage of absorbance and 3 lots. (lot) was performed three times.

※ 세포생존율(%) = (시료 처리군 흡광도/무처리군 흡광도)×100※ Cell survival rate (%) = (Sample absorbance / untreated group absorbance) × 100

NR assayNR assay O.D. Mean ± S.D.
(% of 대조군)
OD Mean ± SD
(% of control)
검액농도 (W/W%)Sample concentration (W / W%) 대조군Control group 1One 0.50.5 0.10.1 0.050.05 0.010.01 제조예1:
조직 배양한 노니 배양세포
Preparation Example 1:
Tissue Cultured Noni Culture Cells
0.229±0.004
(100.0)
0.229 ± 0.004
(100.0)
0.223±0.011
(97.38)
0.223 ± 0.011
(97.38)
0.228±0.008
(99.56)
0.228 ± 0.008
(99.56)
0.238±0.012
(103.93)
0.238 ± 0.012
(103.93)
0.249±0.007
(108.73)
0.249 ± 0.007
(108.73)
0.248±0.018
(108.30)
0.248 ± 0.018
(108.30)
비교제조예1:
노니
Comparative Production Example 1:
Noni
0.229±0.004
(100.0)
0.229 ± 0.004
(100.0)
0.226±0.014
(98.69)
0.226 ± 0.014
(98.69)
0.230±0.010
(100.44)
0.230 ± 0.010
(100.44)
0.241±0.012
(105.24)
0.241 ± 0.012
(105.24)
0.247±0.015
(107.86)
0.247 ± 0.015
(107.86)
0.248±0.009
(108.30)
0.248 ± 0.009
(108.30)

로(Raw) 데이터를 토대로 무처리군의 흡광도와 시료 처리군의 흡광도의 평균을 계산하여 표준편차를 구하였다.The standard deviation was obtained by calculating the average of the absorbance of the untreated group and the absorbance of the sample treated group based on raw data.

표 2 및 표 3에서 보는 바와 같이, 본 발명의 제조예1의 MTT50, NR50 값은 1% 이상이며, 비교제조예1과 비교하여 안전한 원료임을 알 수 있다.As shown in Table 2 and Table 3, MTT 50 , NR 50 value of Preparation Example 1 of the present invention is 1% or more, it can be seen that the raw material is safe compared to Comparative Preparation Example 1.

시험예2: 조직 배양한 노니 배양세포(tissue cultured Test Example 2: Tissue Cultured Tissue Cultured Cells Morinda citirifoliaMorinda citirifolia callus)추출물의 세포보호효과 측정 callus) Measurement of cytoprotective effect of extracts

제조예1과 비교제조예1에 대한 SDS (Sodium dodecyl sulfate) 세포독성에 대한 세포 보호 효과 실험를 실시하였다. Cytoprotective effect experiments were performed on SDS (Sodium dodecyl sulfate) cytotoxicity against Preparation Example 1 and Comparative Preparation Example 1.

사람섬유아세포를 10% 우태아혈청 (FBS), 1% 페니실린-스트렙토마이신을 첨가한 IMDM으로 37℃, 5% CO2 배양기에서 배양하였다. 배양된 사람섬유아세포를 96-멀티웰 플레이트에 각각 1×104 세포/웰로 분주하고 24시간 배양하였다. 배양된 세포의 배지를 2% FBS 배지로 교체하고 SDS (Sodium dodecyl sulfate) 0.002%를 1시간 전처리 후 제조예1과 비교제조예1을 각각 처리 농도 별로 배지에 희석하여 병행 처리한 후 24시간 동안 CO2 인큐베이터에서 배양하였다. 배양이 끝난 세포에, PBS(phosphate buffered saline)에 용해한 MTT 저장 용액(5 mg/㎖)을 새로운 배지에서 10배 희석하고, 이 용액을 세포 각각의 웰에 100㎕씩 첨가하여 37℃에서 4시간 반응시켰다. 반응 후 살아있는 세포는 미토콘드리아에 존재하는 탈수소 효소에 의해 노란색의 수용성 기질인 MTT [3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium-bromide]가 비수용성의 MTT-포마즌 결정으로 환원되므로 이것의 양을 재면 세포 생존율을 측정할 수 있다. 배양 상등액을 제거하고 각각의 웰에 DMSO 200㎕를 첨가하여 세포에서 생성된 MTT-포마즌 결정체를 용해시킨 후 흡수분광광도계(UVmax, Molecular Device, USA)로 포마즌의 흡광도가 최대가 되는 시험필터인 540 ㎚의 파장에서의 O.D값과 참조필터인 630㎚ 파장의 O.D값을 측정하여 그 차이값의 흡광도를 구하였다 (참고문헌 The EMBO Journal(2002)21, 2407-2417외 다수). 세포 보호 효과는 흡광도의 백분율로 나타내었다.Human fibroblasts were cultured in 37 ° C., 5% CO 2 incubator with IMDM with 10% fetal calf serum (FBS) and 1% penicillin-streptomycin. Cultured human fibroblasts were dispensed at 1 × 10 4 cells / well in 96-multiwell plates and incubated for 24 hours. The medium of cultured cells was replaced with 2% FBS medium, and 0.002% of SDS (Sodium dodecyl sulfate) was pretreated for 1 hour, followed by dilution of Preparation Example 1 and Comparative Preparation Example 1 in the medium by treatment concentration for 24 hours. Incubated in a CO 2 incubator. In cultured cells, MTT stock solution (5 mg / ml) dissolved in PBS (phosphate buffered saline) was diluted 10-fold in fresh medium, and 100 µl of each solution was added to each well of the cell, followed by 4 hours at 37 ° C. Reacted. After the reaction, the living cells were dehydrated by the dehydrogenase present in the mitochondria, and the yellow water-soluble substrate MTT [3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium-bromide] was insoluble in water. Since it is reduced to crystals, the amount of this can be measured to determine cell viability. Remove the culture supernatant and add 200 μl of DMSO to each well to dissolve the MTT-formenic crystals produced in the cells, and then use the absorption spectrophotometer (UVmax, Molecular Device, USA) to filter the maximum absorbance of the formazin. The OD value at a wavelength of 540 nm and the OD value at a wavelength of 630 nm as a reference filter were measured to determine the absorbance of the difference (Ref. EMBO Journal (2002) 21, 2407-2417 et al.). The cytoprotective effect is expressed as a percentage of absorbance.

※ 세포생존율(%) = (시료 처리군 흡광도/무처리군 흡광도)×100※ Cell survival rate (%) = (Sample absorbance / untreated group absorbance) × 100

로(Raw) 데이터를 토대로 무처리군의 흡광도와 시료 처리군의 흡광도의 평균을 계산하여 표준편차를 구하였다.The standard deviation was obtained by calculating the average of the absorbance of the untreated group and the absorbance of the sample treated group based on raw data.

MTT assayMTT assay O.D. Mean ± S.D.
(% of 대조군control)
OD Mean ± SD
(% of control)
검액농도 (W/W%)Sample concentration (W / W%) 대조군Control group SDS OnlySDS Only SDS + 0.01SDS + 0.01 SDS + 0.05SDS + 0.05 SDS + 0.1SDS + 0.1 SDS + 0.5SDS + 0.5 제조예1:
조직 배양한 노니 배양세포
Preparation Example 1:
Tissue Cultured Noni Culture Cells
0.421±0.011
(100.0)
0.421 ± 0.011
(100.0)
0.217±0.013
(51.54)
0.217 ± 0.013
(51.54)
0.242±0.009
(57.48)
0.242 ± 0.009
(57.48)
0.299±0.013
(71.02)
0.299 ± 0.013
(71.02)
0.328±0.017
(77.91)
0.328 ± 0.017
(77.91)
0.342±0.010
(81.24)
0.342 ± 0.010
(81.24)
비교제조예1:
노니
Comparative Production Example 1:
Noni
0.421±0.011
(100.0)
0.421 ± 0.011
(100.0)
0.217±0.013
(51.54)
0.217 ± 0.013
(51.54)
0.246±0.011
(58.43)
0.246 ± 0.011
(58.43)
0.283±0.015
(67.22)
0.283 ± 0.015
(67.22)
0.307±0.012
(72.92)
0.307 ± 0.012
(72.92)
0.318±0.007
(75.53)
0.318 ± 0.007
(75.53)

표 4에서 보는 바와 같이, 본 발명의 제조예1의 세포 보호 효과는 외부자극에 대하여 세포 보호 효과를 촉진 시킴을 알 수 있다.As shown in Table 4, it can be seen that the cell protective effect of Preparation Example 1 of the present invention promotes the cell protective effect against external stimulation.

시험예 3. 조직 배양한 노니 배양세포(tissue cultured Test Example 3 Tissue Cultured Tissue Cultured Cells Morinda citirifoliaMorinda citirifolia callus)추출물의 항산화 효과 측정 antioxidative effect of extract

제조예1과 비교제조예1에 대한 항산화 효과 시험을 실시하였다. Antioxidant effect test was carried out for Preparation Example 1 and Comparative Preparation Example 1.

<DPPH (1,1-diphenyl-2 picrylhydrazyl) 라디칼에 의한 항-하이드록실 라디칼 활성(%) 측정><Measurement of anti-hydroxyl radical activity (%) by DPPH (1,1-diphenyl-2 picrylhydrazyl) radicals>

활성 산소에 의한 반응은 거의 대부분 라디칼 반응으로서 자동산화반응 과정이 포함된다. 생체 내에서 자동산화반응을 차단시키는 역할은 항산화제가 담당하고 있다. 전자를 주는 능력으로서 환원력이 클수록 강한 항산화제가 된다. 항산화제의 환원력을 측정하는 시약으로 1,1-디페닐-2-피크릴하이드로질(1,1-diphenyl-2-picrylhydrazyl: DPPH) 라디칼이 있다. DPPH는 화합물 내 질소 중심의 안정화된 구조의 라디칼로 존재한다. 517㎚에서 최대 흡수를 나타내며 환원되면 517㎚에서 흡수가 없어진다. DPPH(D9132, SIGMA)를 메탄올과 증류수의 6:4(v/v) 혼합용매에 녹이고, 상기 DPPH 용액을 513㎚에서 흡광도가 0.6 정도 되도록 맞추었다. DPPH 용액 2㎖를 농도에 따라 희석한 시료 1㎖에 각각 첨가하여 혼합하였다. 상온에서 약 1시간 동안 방치한 후, 흡수분광광도계(UVmax, Molecular Device, USA)를 사용하여 513㎚에서 흡광도를 측정하였으며 그 결과를 하기 표 5에 나타내었다. Reactions by free radicals are almost always radical reactions, including the process of automatic oxidation. Antioxidants are responsible for blocking the automatic oxidation in vivo. The greater the reducing power as an electron-giving ability, the stronger the antioxidant. A reagent that measures the reducing power of antioxidants is the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical. DPPH exists as a radical of a stabilized structure of the nitrogen center in the compound. The maximum absorption at 517 nm is shown and the reduction is absent at 517 nm. DPPH (D9132, SIGMA) was dissolved in a 6: 4 (v / v) mixed solvent of methanol and distilled water, and the DPPH solution was adjusted to have an absorbance of about 0.6 at 513 nm. 2 ml of DPPH solution was added to 1 ml of the diluted sample and mixed. After standing at room temperature for about 1 hour, absorbance at 513 nm was measured using an absorption spectrophotometer (UVmax, Molecular Device, USA) and the results are shown in Table 5 below.

DPPH assayDPPH assay O.D. Mean ± S.D.
(% of 대조군control)
OD Mean ± SD
(% of control)
검액농도 (W/W%)Sample concentration (W / W%) 대조군Control group 1One 0.50.5 0.250.25 0.10.1 0.050.05 제조예1:
조직 배양한 노니 배양세포
Preparation Example 1:
Tissue Cultured Noni Culture Cells
0.866±0.006
(0.00)
0.866 ± 0.006
(0.00)
0.083±0.011
(90.42)
0.083 ± 0.011
(90.42)
0.120±0.006
(86.14)
0.120 ± 0.006
(86.14)
0.284±0.008
(67.21)
0.284 ± 0.008
(67.21)
0.483±0.011
(44.23)
0.483 ± 0.011
(44.23)
0.697±0.010
(19.52)
0.697 ± 0.010
(19.52)
비교제조예1:
노니
Comparative Production Example 1:
Noni
0.866±0.006
(0.00)
0.866 ± 0.006
(0.00)
0.098±0.009
(88.68)
0.098 ± 0.009
(88.68)
0.198±0.011
(77.14)
0.198 ± 0.011
(77.14)
0.378±0.010
(56.35)
0.378 ± 0.010
(56.35)
0.631±0.015
(27.14)
0.631 ± 0.015
(27.14)
0.811±0.006
(6.35)
0.811 ± 0.006
(6.35)

표 5에 나타난 바와 같이, 제조예1은 우수한 항산화 효과를 나타내었다.As shown in Table 5, Preparation Example 1 showed an excellent antioxidant effect.

시험예4: 조직 배양한 노니 배양세포(tissue cultured Test Example 4: tissue cultured noni tissue cells Morinda citirifoliaMorinda citirifolia callus)추출물의 타이로시나제 활성 및 멜라닌 합성 억제 효과 측정 measurement of tyrosinase activity and inhibitory effect of melanin synthesis

시험예4-1. 타이로시나제 활성 저해 시험Test Example 4-1. Tyrosinase Activity Inhibition Test

제조예1 및 비교제조예1의 미백활성을 조사하기 위해 타이로시나제 활성 저해 시험을 실시하였다. 실험을 위해, 타이로시나제 효소액은 버섯 타이로시나제 (mushroom tyrosinase, T-3824, 1530U/㎎, Sigma)를 1000U/㎖이 되도록 인산염 완충액(pH 6.5)으로 녹여 준비하였으며, 기질액은 L-타이로신(L-tyrosine, 45160-0410,Junsei chemical co. Ltd)을 1.5 mM이 되도록 인산염 완충액(pH 6.5)으로 녹여 준비하였다.Preparation Example 1 and Comparative Preparation Example 1 Tyrosinase activity inhibition test was conducted to investigate the whitening activity. For the experiment, tyrosinase enzyme solution was prepared by dissolving mushroom tyrosinase (mushroom tyrosinase, T-3824, 1530U / mg, Sigma) in phosphate buffer (pH 6.5) to 1000U / ml, and the substrate solution was L. -Tyrosine (L-tyrosine, 45160-0410, Junsei chemical co. Ltd) was prepared by dissolving in phosphate buffer (pH 6.5) to 1.5 mM.

제조예1 및 비교제조예1을 완충액에 농도 별로 희석하여 검액을 준비하였다. 검액 170㎕, 타이로시나제 효소액 10㎕를 넣고 37℃에서 10분간 방치하였다. 여기에 기질액 20㎕를 넣은 다음 37℃에서 10분간 반응시킨 후, 바로 얼음 중에 5분간 방치한 후, 흡수분광광도계(UVmax, Molecular Device, USA)를 이용하여 파장 490㎚에서 흡광도를 측정하였다. 상기에서 측정된 흡광도를 하기 수학식 1에 대입하여 타이로시나제 활성저해율을 계산하여 하기 표 6에 나타내었다. 검액 대신 인산염 완충액(pH 6.5)을 넣어 조작한 액을 공시험액으로, 기질액 대신 인산염 완충액(pH 6.5)을 넣어 조작한 액을 보정액으로 하였다.Preparation Example 1 and Comparative Preparation Example 1 were prepared by diluting each sample in a buffer at different concentrations. 170 μl of sample solution and 10 μl of tyrosinase enzyme solution were added thereto, and the mixture was left at 37 ° C. for 10 minutes. 20 μl of substrate solution was added thereto, followed by reaction for 10 minutes at 37 ° C., and then left for 5 minutes in ice, and then absorbance was measured at wavelength 490 nm using an absorption spectrophotometer (UVmax, Molecular Device, USA). Substituting the absorbance measured in the above Equation 1 to calculate the tyrosinase activity inhibition rate is shown in Table 6 below. A solution prepared by adding phosphate buffer (pH 6.5) instead of the sample solution was used as a blank test solution, and a solution prepared by adding phosphate buffer (pH 6.5) instead of the substrate solution was used as a calibration solution.

<수학식 1>&Quot; (1) &quot;

타이로시나제 활성저해율 (%) = 100 - (A-A')/(B-B') X 100Tyrosinase activity inhibition rate (%) = 100-(A-A ') / (B-B') X 100

A: 검액 반응 후의 흡광도A: absorbance after the liquid reaction

B: 공시험액의 반응 후의 흡광도B: absorbance after reaction of blank test solution

A': 검액의 보정액A ': Correction liquid of the test liquid

B': 공시험액의 보정액B ': Correction amount of blank

타이로시나제
활성 저해 측정
Tyrosinase
Activity inhibition measurement
O.D. Mean ± S.D.
(% of 대조군)
OD Mean ± SD
(% of control)
검액농도 (W/W%)Sample concentration (W / W%) 대조군Control group 55 2.52.5 1One 0.50.5 제조예1:
조직 배양한 노니 배양세포
Preparation Example 1:
Tissue Cultured Noni Culture Cells
0.247±0.011
(0.00)
0.247 ± 0.011
(0.00)
0.035±0.09
(85.83)
0.035 ± 0.09
(85.83)
0.074±0.012
(70.04)
0.074 ± 0.012
(70.04)
0.125±0.005
(49.39)
0.125 ± 0.005
(49.39)
0.197±0.009
(20.24)
0.197 ± 0.009
(20.24)
비교제조예1:
노니
Comparative Production Example 1:
Noni
0.247±0.011
(0.00)
0.247 ± 0.011
(0.00)
0.046±0.011
(81.38)
0.046 ± 0.011
(81.38)
0.087±0.013
(64.78)
0.087 ± 0.013
(64.78)
0.149±0.008
(39.68)
0.149 ± 0.008
(39.68)
0.218±0.013
(11.74)
0.218 ± 0.013
(11.74)

시험예4-2: 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물의 농도에 따른 멜라닌 합성 억제 측정 실험 Test Example 4-2: Measurement of melanin synthesis inhibition according to the concentration of tissue cultured Morinda citirifolia callus extract

제조예1 및 비교제조예1에 대하여 B-16 멜라노마 세포(Melanoma cell: 연세대학교 원주 의과대학 분양)를 이용하여 미백효과를 측정하였다. 측정방법으로는 블랙 마우스에서 유래된 B-16 멜라노마 세포를 10% FBS(GIBCO., USA)가 함유된 DMEM으로 6 웰 조직 배양 접시에 2 × 104 세포/웰 농도로 2㎖씩 첨가하고 5% CO2, 37℃조건하에서 24시간 배양하였다. 배양 후 배지를 제거하고 10% FBS, 2uM α-MSH(Sigma., USA, Melanocyte stimulating Hormone)과 2mM 테오필린(Sigma., USA, theophylline)이 함유된 DMEM으로 교체한 후, 조직 배양한 산삼 부정근 추출물을 동일배지로 적당량 희석한 후 각각 첨가하고 나서, 5% CO2, 37℃ 조건하에서 세포가 웰의 바닥에 약 80% 이상 될 때까지 배양하였다. 배양 후 배지를 제거한 다음 PBS(Sigma., USA, Phosphate buffered Saline)로 세척하고 트립신으로 처리하여 세포를 회수하였다. 회수된 세포를 5000rpm으로 10분간 원심 분리한 후 상등액을 제거하였다. 상등액이 제거된 세포를 60℃ 항온기에서 24시간 건조시킨 후 1N NaOH를 첨가하여 세포내의 멜라닌을 용해시켰다. 용해된 멜라닌을 흡수분광광도계(Uvmax, Molecular Device, USA)를 이용하여 파장 490 ㎚에서 흡광도를 측정하였다. For Preparation Example 1 and Comparative Preparation Example 1, the whitening effect was measured using B-16 melanoma cells (prepared Yonsei University Wonju Medical College). As a measuring method, B-16 melanoma cells derived from black mice were added to a 6 well tissue culture dish at 2 × 10 4 cells / well concentration with DMEM containing 10% FBS (GIBCO., USA). 5% CO 2 , and incubated for 24 hours under 37 ℃ conditions. After incubation, the medium was removed, and then replaced with DMEM containing 10% FBS, 2uM α-MSH (Sigma., USA, Melanocyte stimulating Hormone) and 2 mM theophylline (Sigma., USA, theophylline), and then cultured wild ginseng root muscle extract Were diluted in the same medium and added, respectively, and then cultured under 5% CO 2 , 37 ° C. until the cells were at least about 80% at the bottom of the well. After incubation, the medium was removed, washed with PBS (Sigma., USA, Phosphate buffered Saline) and treated with trypsin to recover the cells. The recovered cells were centrifuged at 5000 rpm for 10 minutes and the supernatant was removed. Cells from which the supernatant was removed were dried for 24 hours at 60 ° C. incubator and lysed melanin by adding 1N NaOH. The dissolved melanin was measured for absorbance at wavelength 490 nm using an absorption spectrophotometer (Uvmax, Molecular Device, USA).

<수학식 2>
멜라닌 합성 억제율 (%) = (1- A/A’) X 100
&Quot; (2) &quot;
Melanin synthesis inhibition rate (%) = (1- A / A ') X 100

A : 멜라닌 농도 A’: 세포수A: melanin concentration A ': number of cells

삭제delete

삭제delete

삭제delete

삭제delete

멜라닌 합성억제 측정Melanin Synthesis Inhibition O.D. Mean ± S.D.
(% of 대조군)
OD Mean ± SD
(% of control)
검액농도 (W/W%)Sample concentration (W / W%) 대조군Control group 0.250.25 0.10.1 0.050.05 0.010.01 제조예1:
조직 배양한 노니 배양세포
Preparation Example 1:
Tissue Cultured Noni Culture Cells
0.238±0.010
(0.00)
0.238 ± 0.010
(0.00)
0.046±0.008
(80.67)
0.046 ± 0.008
(80.67)
0.089±0.0015
(62.61)
0.089 ± 0.0015
(62.61)
0.161±0.012
(32.35)
0.161 ± 0.012
(32.35)
0.219±0.009
(7.98)
0.219 ± 0.009
(7.98)
비교제조예1:
노니
Comparative Production Example 1:
Noni
0.238±0.010
(0.00)
0.238 ± 0.010
(0.00)
0.073±0.012
(69.33)
0.073 ± 0.012
(69.33)
0.112±0.018
(52.94)
0.112 ± 0.018
(52.94)
0.196±0.007
(17.65)
0.196 ± 0.007
(17.65)
0.225±0.012
(5.46)
0.225 ± 0.012
(5.46)

표 6 및 표 7에 나타난 바와 같이, 제조예1은 타이로시나제 활성을 농도 의존적으로 억제하였으며, 세포 내 멜라닌 생성억제 효과가 우수하였다.As shown in Table 6 and Table 7, Preparation Example 1 inhibited tyrosinase activity in a concentration-dependent manner, and was excellent in inhibiting melanin production in the cell.

시험예5: 조직 배양한 노니 배양세포(tissue cultured Test Example 5: tissue cultured noni tissue cells Morinda citirifoliaMorinda citirifolia callus)추출물의 콜라겐 생합성 측정 measurement of collagen biosynthesis of extract

피부 주름의 발생 원인 중 하나로 피부교원질 즉 콜라겐의 결핍을 들고 있다. 콜라겐은 피부 진피를 구성하는 주요 단백질로서 피부 구조와 탄력을 유지하는 역할을 하고 있다. 콜라겐은 나이가 들면서 생성의 감소를 보이며 분해도 증가되어 피부 진피층의 함몰을 유도하여 피부의 주름을 생성하는 것으로 알려져 있다. One of the causes of skin wrinkles is a deficiency of collagen, or collagen. Collagen is a major protein that makes up the skin dermis and plays a role in maintaining skin structure and elasticity. Collagen is known to show a decrease in production with increasing age and to increase the decomposition to induce depression of the dermal dermal layer to produce wrinkles of the skin.

<콜라겐 생합성량 측정><Measurement of collagen biosynthesis amount>

본 발명에 따른 화장료의 주름개선 효과를 조사하기 위해 섬유아세포를 이용한 콜라겐 생합성 촉진 시험(SircolTM Soluble Collagen Assay Kit)을 실시하였다. In order to investigate the anti-wrinkle effect of the cosmetics according to the present invention, a collagen biosynthesis promoting test (Sircol Soluble Collagen Assay Kit) using fibroblasts was performed.

배양한 사람섬유아세포를 12웰 세포 배양접시에 1×105 세포/웰이 되도록 5% FBS를 포함하는 배지에 분주하여 24시간 배양하고, 2% FBS를 포함하는 배지에 조직 배양한 제조예1 및 비교제조예1을 각각 처리 농도 별로 희석하여 세포에 처리하고 48시간 배양하여 하기 실험에 사용하였다. 상기 섬유아세포(fibroblast)에서 실제적으로 콜라겐의 합성이 증가되었음을 확인하기 위하여 Biocolor 사의 SircolTM 용해 콜라겐 분석 키트(Soluble Collagen Assay kit)를 구입하여 제품 매뉴얼의 실험 방법에 따라 콜라겐 양을 측정하였다. SircolTM 용해 콜라겐 분석 키트는 세포를 배양 하는 동안 배양 배지로 분비된 콜라겐과 염색시약의 결합에 의한 방법으로 확인 할 수 있는 정량방법이다. 상세하게는, 배양 상등액 100㎕에 염색 시약(dye reagent, 피크릭산에 Sirius red reagent이 포함된 용액) 1㎖을 첨가하고 30분간 반응시켰다(콜라겐 생성량에 따라 시험 시 배양액을 농축하거나 배양 상등액을 200㎕까지 염색 시약 1㎖와 반응시킬 수 있다.) 씨리어스 레드(Sirius red)는 음이온계 색소로서 콜라겐에 특이적으로 결합한다. 30분간 반응시킨 후 반응액을 12,000× g 이상에서 10분간 원심분리하여 콜라겐-색소 결합체를 침전시켰다. 침전물에 알칼리 시약 1.0㎖을 첨가하여 실온에서 5분 동안 용해시켰다. 상기 용액의 흡광도를 흡수분광광도계(UVmax, Molecular Device, USA)를 이용하여 540㎚에서 측정하여 하기 표 8에 나타내었으며, 이를 비시험군의 흡광도 비교하여 콜라겐 생합성 촉진 효과를 평가하였다.Cultured human fibroblasts were dispensed in a medium containing 5% FBS to be 1 × 10 5 cells / well in a 12 well cell culture dish and incubated for 24 hours, followed by tissue culture in a medium containing 2% FBS. And Comparative Preparation Example 1 were diluted for each treatment concentration, treated to cells, and cultured for 48 hours, and used in the following experiment. In order to confirm that the synthesis of collagen was actually increased in the fibroblasts, Biocolor's Sircol TM soluble collagen assay kit (Soluble Collagen Assay kit) was purchased, and the amount of collagen was measured according to the experimental method of the product manual. Sircol TM soluble collagen assay kit is a quantitative method that can be identified by combining collagen and staining reagent secreted into the culture medium during cell culture. Specifically, 1 ml of a dyeing reagent (a solution containing Sirius red reagent in picric acid) was added to 100 µl of the culture supernatant and allowed to react for 30 minutes (concentration of the culture solution or the culture supernatant during the test depending on the amount of collagen production). Up to 200 μl can be reacted with 1 ml of the dyeing reagent.) Sirius red is an anionic pigment that specifically binds to collagen. After reacting for 30 minutes, the reaction solution was centrifuged at 12,000 × g for 10 minutes to precipitate the collagen-pigment conjugate. 1.0 ml of alkaline reagent was added to the precipitate and dissolved for 5 minutes at room temperature. Absorbance of the solution was measured at 540 nm using an absorbance spectrophotometer (UVmax, Molecular Device, USA), and is shown in Table 8 below. The effect of promoting collagen biosynthesis was evaluated by comparing the absorbance of the test group.

시료sample O.D. Mean ± S.D.
(% of 대조군)
OD Mean ± SD
(% of control)
검액농도 (W/W%)Sample concentration (W / W%) 대조군Control group 0.010.01 0.050.05 0.10.1 0.50.5 제조예1:
조직 배양한 노니 배양세포
Preparation Example 1:
Tissue Cultured Noni Culture Cells
0.424±0.032
(100)
0.424 ± 0.032
(100)
0.451±0.018
(106.37)
0.451 ± 0.018
(106.37)
0.489±0.021
(115.33)
0.489 ± 0.021
(115.33)
0.568±0.023
(133.96)
0.568 ± 0.023
(133.96)
0.554±0.016
(131.13)
0.554 ± 0.016
(131.13)
비교제조예1:
노니
Comparative Production Example 1:
Noni
0.424±0.032
(100)
0.424 ± 0.032
(100)
0.463±0.015
(109.20)
0.463 ± 0.015
(109.20)
0.481±0.019
(113.68)
0.481 ± 0.019
(113.68)
0.529±0.031
(124.76)
0.529 ± 0.031
(124.76)
0.546±0.022
(128.77)
0.546 ± 0.022
(128.77)

표 8에 나타난 바와 같이, 제조예1은 콜라겐 생합성 효과가 우수함을 확인하였다. As shown in Table 8, Preparation Example 1 confirmed that the collagen biosynthesis effect is excellent.

실시예1: 조직 배양한 노니 배양세포(tissue cultured Example 1 Noni Culture Cells Tissue Cultured Morinda citirifoliaMorinda citirifolia callus)추출물을 함유하는 에센스의 제조 callus) Preparation of essence containing extract

제조예1을 포함하는 에센스를 하기 표 9의 조성에 따라 제조하였다. An essence comprising Preparation Example 1 was prepared according to the composition of Table 9 below.

성분명Ingredient Name 함량(중량%)Content (% by weight) AA 1,3-부틸렌글리콜1,3-butylene glycol 1.01.0 글리세린glycerin 1.01.0 카보머Carbomer 0.20.2 글리세릴 메타크릴레이트Glyceryl Methacrylate 0.350.35 파라벤Parabens 0.200.20 정제수Purified water 잔량Balance BB 수산화칼륨Potassium hydroxide 0.060.06 CC PEG-6-하이드로 제네이티드 캐스터 오일PEG-6-hydrogenated castor oil 1.01.0 향료Spices 0.50.5 DD 제조예1Preparation Example 1 5.05.0 system 100.00100.00

A를 충분히 분산, 습윤하여 균일한 겔(Gel)상이 되도록 하고, B를 첨가하여 중화하였다. (A+B)에 C를 첨가하여 균일교반하여 가용화시킨 후, D를 실온에서 첨가하여 균일하게 분포되도록 교반하고, 용기에 담아 제품화하였다. A was sufficiently dispersed and wetted to form a uniform gel, and neutralized by adding B. C was added to (A + B), uniformly stirred and solubilized, and then D was added at room temperature, stirred to distribute uniformly, and put into a container to produce a product.

실시예2 내지 4: 조직 배양한 노니 배양세포(tissue cultured Examples 2 to 4: tissue cultured noni tissue cells Morinda citirifoliaMorinda citirifolia callus)추출물을 포함하는 유연화장수(스킨)의 제조 callus) Preparation of Softener (Skin) Containing Extracts

제조예1을 포함하는 화장료 조성물 중 유연화장수(스킨)의 실시예는 하기 표 10과 같다. Examples of the flexible longevity (skin) in the cosmetic composition containing Preparation Example 1 are shown in Table 10 below.

성분ingredient 실시예2Example 2 실시예3Example 3 실시예4Example 4 함량(중량%)Content (% by weight) 함량(중량%)Content (% by weight) 함량(중량%)Content (% by weight) 조예1 Article 1 10.0010.00 5.005.00 2.002.00 부틸렌글아이콜Butylene glycol 2.002.00 2.002.00 2.002.00 글리세린glycerin 3.003.00 3.003.00 3.003.00 올레일알코올Oleyl alcohol 2.002.00 2.002.00 2.002.00 폴리솔베이트 20Polysorbate 20 1.001.00 1.001.00 1.001.00 에탄올ethanol 6.006.00 6.006.00 6.006.00 방부제antiseptic 0.50.5 0.50.5 0.50.5 incense 0.50.5 0.50.5 0.50.5 정제수Purified water 잔량Balance 잔량Balance 잔량Balance system 100.00100.00 100.00100.00 100.00100.00

실시예5 내지 7: 조직 배양한 노니 배양세포(tissue cultured Examples 5 to 7: Tissue cultured tissue cultured Morinda citirifoliaMorinda citirifolia callus)추출물을 포함하는 영양유액(밀크로션)의 제조 callus) Preparation of nutritional milk (milk lotion) containing extract

제조예1을 함유하는 화장료 조성물 중 영양유액(밀크로션)의 처방예는 하기 표 11와 같다. Formulation example of nutrient emulsion (milk lotion) in the cosmetic composition containing Preparation Example 1 is shown in Table 11.

성분 ingredient 실시예5Example 5 실시예6Example 6 실시예7Example 7 함량(중량%)Content (% by weight) 함량(중량%)Content (% by weight) 함량(중량%)Content (% by weight) 제조예1Preparation Example 1 10.0010.00 5.005.00 2.002.00 부틸렌글아이콜Butylene glycol 4.004.00 4.004.00 4.004.00 글리세린glycerin 3.003.00 3.003.00 3.003.00 올레일알코올Oleyl alcohol 1.001.00 1.001.00 1.001.00 폴리솔베이트20Polysorbate20 1.001.00 1.001.00 1.001.00 방부제antiseptic 0.50.5 0.50.5 0.50.5 incense 0.50.5 0.50.5 0.50.5 정제수Purified water 잔량Balance 잔량Balance 잔량Balance system 100.00100.00 100.00100.00 100.00100.00

실시예 8 내지 10: 조직 배양한 노니 배양세포(tissue cultured Examples 8 to 10 tissue cultured noni tissue cells Morinda citirifoliaMorinda citirifolia callus)추출물을 포함하는 크림의 제조 callus) Preparation of cream containing extract

제조예1을 함유하는 화장료 조성물 중 크림의 처방예는 하기 표 12와 같다. Formulation example of the cream in the cosmetic composition containing Preparation Example 1 is shown in Table 12 below.

성분ingredient 실시예8Example 8 실시예9Example 9 실시예10Example 10 함량(중량%)Content (% by weight) 함량(중량%)Content (% by weight) 함량(중량%)Content (% by weight) 제조예1Preparation Example 1 10.0010.00 5.005.00 2.002.00 부틸렌글아이콜Butylene glycol 2.002.00 2.002.00 2.002.00 글리세린glycerin 4.004.00 4.004.00 4.004.00 포타슘하이드록사이드Potassium hydroxide 0.100.10 0.100.10 0.100.10 토코페릴 아세테이트Tocopheryl acetate 1.01.0 1.01.0 1.01.0 유동파라핀Liquid paraffin 5.05.0 5.05.0 5.05.0 스쿠알란Squalane 5.05.0 5.05.0 5.05.0 마카디미아넛트오일Macadamia Nut Oil 10.010.0 10.010.0 10.010.0 폴리솔베이트 60Polysorbate 60 1.01.0 1.01.0 1.01.0 소르비탄세스퀴올레이트Sorbitan sesquioleate 1.01.0 1.01.0 1.01.0 카보머Carbomer 0.30.3 0.30.3 0.30.3 방부제antiseptic 0.50.5 0.50.5 0.50.5 incense 0.50.5 0.50.5 0.50.5 정제수Purified water 잔량Balance 잔량Balance 잔량Balance system 100.00100.00 100.00100.00 100.00100.00

Claims (8)

조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus) 추출물을 포함하고,Tissue cultured noni cultured cells (tissue cultured Morinda citirifolia callus) extract, 항산화, 피부 주름 개선, 피부 미백 또는 피부보호용으로 사용되는 것을 특징으로 하는 화장료 조성물.Cosmetic composition, characterized in that used for antioxidant, skin wrinkle improvement, skin whitening or skin protection. 청구항 1에 있어서, 조성물 총 중량에 대하여, 상기 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물을 0.1 내지 10.0 중량%로 포함하는 것을 특징으로 하는 화장료 조성물.The cosmetic composition of claim 1, comprising 0.1 to 10.0 wt% of tissue cultured Morinda citirifolia callus extract based on the total weight of the composition. 청구항 1에 있어서, 상기 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물이 조직 배양한 노니 배양세포를 정제수, C1 내지 C4의 알코올 및 C1 내지 C5의 알킬렌글리콜로 이루어진 군으로부터 선택되는 1종 이상의 용매를 사용하여 추출하는 것을 특징으로 하는 화장료 조성물.The noni culture cells of tissue cultured noni culture cells (tissue cultured Morinda citirifolia callus) extract is selected from the group consisting of purified water, alcohol of C1 to C4 and alkylene glycol of C1 to C5. Cosmetic composition, characterized in that the extraction using more than one solvent. 삭제delete 청구항 1에 있어서, 상기 화장료 조성물은 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 영양로션, 마사지크림, 영양크림, 핸드크림, 파운데이션, 메이크업베이스, 트윈케익, 마스카라, 에센스, 영양에센스, 팩, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저 중에서 선택되는 형태로 제형화되는 것을 특징으로 하는 화장료 조성물.The method of claim 1, wherein the cosmetic composition is a skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, nutrition lotion, massage cream, nutrition cream, hand cream, foundation, makeup base, twin cake, mascara, essence, nutrition Cosmetic composition, characterized in that formulated in the form selected from essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser. a) 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)를 정제수, C1 내지 C4의 알코올 및 C1 내지 C5의 알킬렌글리콜로 이루어진 군으로부터 선택되는 1종 이상의 추출용매에 3 내지 30일 동안 침적하여 침적용액을 형성하는 단계; 및 a) tissue cultured Noni cultured Morinda citirifolia callus was immersed in at least one extractant selected from the group consisting of purified water, C1 to C4 alcohol and C1 to C5 alkylene glycol for 3 to 30 days Forming an immersion solution; And b)상기 침적용액을 여과하여 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물을 얻는 단계를 포함하는 조직 배양한 노니 배양세포 추출물의 제조방법.b) a method of producing a tissue cultured noni culture cell extract comprising the step of obtaining a tissue cultured Morinda citirifolia callus extract by filtration of the deposition solution. 청구항 6에 있어서, 상기 추출용매가 에탄올; 에탄올 및 1,3-부틸렌글리콜; 에탄올 및 프로필렌글리콜; 및 에탄올 및 펜틸렌글리콜으로 이루어진 군에서 선택되는 1종 이상인 것을 특징으로 하는 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물의 제조방법. The method of claim 6, wherein the extraction solvent is ethanol; Ethanol and 1,3-butylene glycol; Ethanol and propylene glycol; And non-cultured tissue cultured Morinda citirifolia callus extract, characterized in that at least one selected from the group consisting of ethanol and pentylene glycol. 청구항 6에 있어서, 상기 b)단계는 상기 추출용매를 제거하는 단계를 더 포함하는 것을 특징으로 하는 조직 배양한 노니 배양세포(tissue cultured Morinda citirifolia callus)추출물의 제조방법. The method of claim 6, wherein the step b) further comprises the step of removing the extracting solvent tissue cultured noni cultured cells (tissue cultured Morinda citirifolia callus) extract manufacturing method.
KR1020090020815A 2009-03-11 2009-03-11 A cosmetic composition comprising an extract of the tissue cultured morinda citirifolia callus extracts and a preparation method of the extract KR101093863B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020090020815A KR101093863B1 (en) 2009-03-11 2009-03-11 A cosmetic composition comprising an extract of the tissue cultured morinda citirifolia callus extracts and a preparation method of the extract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020090020815A KR101093863B1 (en) 2009-03-11 2009-03-11 A cosmetic composition comprising an extract of the tissue cultured morinda citirifolia callus extracts and a preparation method of the extract

Publications (2)

Publication Number Publication Date
KR20100102437A KR20100102437A (en) 2010-09-24
KR101093863B1 true KR101093863B1 (en) 2011-12-13

Family

ID=43007536

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020090020815A KR101093863B1 (en) 2009-03-11 2009-03-11 A cosmetic composition comprising an extract of the tissue cultured morinda citirifolia callus extracts and a preparation method of the extract

Country Status (1)

Country Link
KR (1) KR101093863B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102321147B1 (en) * 2019-10-29 2021-11-03 유영국 Cosmetic composition comprising Extracts of Ngoc Linh Ginseng, Curcuma longa, and Morinda citrifolia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005145945A (en) 2003-11-14 2005-06-09 Tahiti Ambition:Kk Skin function-activating cosmetic composition
JP2007055963A (en) 2005-08-26 2007-03-08 Okinawa Pref Gov Anti-oxidative substance
KR100844275B1 (en) 2006-12-20 2008-07-07 주식회사 코리아나화장품 Cosmetic Composition for Preventing Skin Aging Comprising the Morinda citrifolia Extract As Active Ingredient

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005145945A (en) 2003-11-14 2005-06-09 Tahiti Ambition:Kk Skin function-activating cosmetic composition
JP2007055963A (en) 2005-08-26 2007-03-08 Okinawa Pref Gov Anti-oxidative substance
KR100844275B1 (en) 2006-12-20 2008-07-07 주식회사 코리아나화장품 Cosmetic Composition for Preventing Skin Aging Comprising the Morinda citrifolia Extract As Active Ingredient

Also Published As

Publication number Publication date
KR20100102437A (en) 2010-09-24

Similar Documents

Publication Publication Date Title
KR20200026646A (en) Cosmetic Composition for Improving Skin Condition Comprising Plant cell complex cultures to improve skin radiance and vitality
KR20150139688A (en) The Extract Of The Citrus grandis Osbeck Having Skin Whitening Activity And Cosmetic Composition Containing The Same
KR101402550B1 (en) Antioxidizing Functional Cosmetic Compositions for Containing Extracted/Fermented Dendropanax morbifera Products and Functional Cosmetics Produced Thereby
KR101312965B1 (en) The cosmetic composition for anti-wrinkle comprising the mixture of extract of Allium cepa, Symphytum officinale, Eclipta prostrate, and Theobroma cacao
KR100443588B1 (en) Cosmetic composition containing paeonia suffruticosa andrews extract and albizzia julibrissin dura extract having anti-ageing effect
KR20170048904A (en) Cosmetic compositions for skin whitening containing costunolide from natural extracts
KR101093901B1 (en) A cosmetic composition comprising an extract of tissue cultured anoectochilus formosanus and a preparation method of the extract of tissue cultured anoectochilus formosanus
KR101627237B1 (en) COSMETIC COMPOSITION COMPRISING Aconogonum polymorphum EXTRACT FOR SKIN WHITENING
KR101295336B1 (en) A Cosmetic Composition Comprising Fagopyrum Tataricum Extract And Preparing Method Thereof
KR101005556B1 (en) A cosmetic composition comprising an extract of saxifraga caespitosa var. uniflora and a preparation method of the extract
KR101093863B1 (en) A cosmetic composition comprising an extract of the tissue cultured morinda citirifolia callus extracts and a preparation method of the extract
CN106413687A (en) Product containing Rhodiola extract and Ginkgo biloba extract, and preparation method and use thereof
KR101124968B1 (en) Cosmetic Composition containing Rumex crispus and Pinus strobus bark extract for whitening
KR101618180B1 (en) Cosmetic composition comprising an extract of the tissue-cultured raoulia australis shoot
KR101083028B1 (en) Cosmetic Composition for Whitening
KR102168533B1 (en) Cosmetic composition for whitening or improving the facial color containing herb extracts
KR100883773B1 (en) Cosmetic compositions comprising fermenting extracts of citrus junos fruit or poncirus trifoliata fruit with salt
KR20090123266A (en) Cosmetic compositions containing the extracts of aster spathulifolius maxim or aster spathulifolius var.oharai, and method of preparing the extracts
KR100999958B1 (en) A cosmetic composition comprising an extract of Saxifraga caespitosa and a fabrication method of an extract of Saxifraga caespitosa
KR102289943B1 (en) Cosmetic composition containing complex extracts of Chrysanthemum Sibiricum, Viscum Album, Selaginella Tamariscina, Portulaca Oleracea and Perilla Frutescens
KR20140071716A (en) Cosmetic composition comprising the extract of Akebia quinata as active ingredi ent
KR102326086B1 (en) Composition for Improving Skin Conditions Having Skin Whitening, Moisturizing, Anti-Wrinkle and Skin Barrier Property Comprising Complex Extracts of Broussonetia kazinoki as Active Ingredient
KR101195576B1 (en) Cosmetic Composition Cyperus Papyrus Extracts for Skin whitenig
KR20230006131A (en) Cosmetic composition having skin whitening effect
KR20240107264A (en) Composition for Improving Skin Conditions with Improved Skin Elasticity and Winkles, Anti-inflammatory, Whitening, Moisturizing, Skin Barrier, Regeneration, Pore Shrinkage, and Antioxidant Property Comprising Plant Complex Extracts as Active Ingredient

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20141113

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20151110

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20161122

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20171106

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20181204

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20191121

Year of fee payment: 9